natgillin/translations-raw huggingface dataset:
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychoticand risperidone-responsive patients, while being comparable to clozapine-responsive patients. 
engl. single photon emission computed tomography) snimanja u bolesnika sa shizofrenijom otkrila su da bolesnici koji reagiraju na olanzapin imaju manju zauzetost strijatalnih D2 receptora od bolesnika koji su reagirali na neke druge antipsihotike i risperidon, dok je zauzetost bila usporediva s onom u bolesnika koji su reagirali na klozapin.
Thromboembolism Temporal association of olanzapine treatment and venous thromboembolism has been reported uncommonly (≥0.1% and <1%). 
Vremenska povezanost liječenja olanzapinom i venske tromboembolije (VTE) zabilježena je manje često (<0,01% i <1%).
The most frequently (seen in ≥1% of patients ) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema. 
Najčešće zabilježene nuspojave (uočene u ≥1% bolesnika) povezane s primjenom olanzapina u kliničkim ispitivanjima bile su somnolencija, povećanje tjelesne težine, eozinofilija, povišene vrijednosti prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glukozurija, povećan apetit, omaglica, akatizija, parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazni asimptomatski porast razina jetrenih aminotransferaza
There was a 3-fold increase in CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3% vs. 0.4%, respectively). 
U bolesnika liječenim olanzapinom zabilježen je trostruki porast CV štetnih događaja u usporedbi s bolesnicima koji su liječeni placebom (1,3% u odnosu na 0,4%).
Development or exacerbation of diabetes occasionally associated with ketoacidosis or coma, including some fatal cases (see section 4.4)11 
Razvoj ili egzacerbacija dijabetesa ponekad povezana s ketoacidozom ili komom, uključujući i neke slučajeve sa smrtnim ishodom (vidjeti dio 4.4)11
Brampton Road, Hampden Park Eastbourne, East Sussex, BN22 9AG United Kingdom 
Brampton Road, Hampden Park Eastbourne, East Sussex, BN22 9AG Ujedinjeno Kraljevstvo
Seizures where in most cases a history of seizures or risk factors for seizures were reported11 
Napadaji u većini slučajeva kada su zabilježeni napadaji u anamnezi ili čimbenici rizika za nastanak napadaja11 Distonija
Olanzapine Teva contains the active substance olanzapine. 
Olanzapin Teva sadrži djelatnu tvar olanzapin.
Glucosuria Increased appetite 
Povećani apetit
In female versus male subjects the mean elimination half-life was somewhat prolonged (36.7 versus 32.3 hr) and the clearance was reduced (18.9 versus 27.3 l/hr). 
U žena je srednja vrijednost poluvremena eliminacije nešto duža u odnosu na muškarce (36,7 u odnosu na 32,3 sata), a klirens je smanjen (18,9 u odnosu na 27,3 l/sat).
Priapism12 
Prijapizam12
Olanzapine Teva 2.5 mg/5 mg/7.5 mg/10 mg film-coated tablets Colour mixture white (polydextrose, hypromellose, glycerol triacetate, macrogol 8000, titanium dioxide E171) 
Olanzapin Teva 2,5 mg/5 mg/7,5 mg/10 mg filmom obložene tablete smjesa bijele boje (polidekstroza, hipromeloza, gliceroltriacetat, makrogol 8000, titanijev dioksid (E171))
- Weight gain has been seen in patients taking Olanzapine Teva. 
- Opaženo je povećanje tjelesne težine u bolesnika koji uzimaju Olanzapin Teva.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. 
Bolesnici s rijetkim nasljednim poremećajem nepodnošenja galaktoze, nedostatkom Lapp laktaze ili glukoza-galaktoza malapsorpcijom ne bi trebali uzimati ovaj lijek.
(See sections 4.5 and 5.2) 
(vidjeti dijelove 4.4 i 4.8).
How to take Olanzapine Teva 
Kako uzimati Olanzapin Teva
Following short term treatment (median duration 47 days), weight gain ≥7% of baseline body weight was very common (22.2%), ≥15% was common (4.2%) and ≥25% was uncommon (0.8%). 
Nakon kratkotrajnog liječenja (medijan trajanja 47 dana), povećanje tjelesne težine ≥7% od početne tjelesne težine bilo je vrlo često (22,2%), povećanje ≥15% bilo je često (4,2%), a ≥25% bilo je manje često (0,8%).
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. 
Bolesnici s rijetkim nasljednim poremećajem nepodnošenja fruktoze, glukoza-galaktoza malapsorpcijom ili saharoza-izomaltaza insuficijencijom ne smiju uzimati ovaj lijek.
Elevated glucose levels4 
Povišene razine glukoze4
Rhabdomyolysis11 
Rabdomioliza11
Keep this medicine out of the sight and reach of children. 
Kako čuvati Olanzapin Teva Lijek čuvajte izvan pogleda i dohvata djece.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu<, and on the website of {name of MS Agency (link)}>. 
{MM/GGGG} Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove http://www.ema.europa.eu<, kao i na internetskoj stranici {naziv nadležnog tijela države članice
See package leaflet for further information. 
Vidjeti uputi o lijeku za više informacija.
Poligono Industrial Malpica, c/C, no. 4, 50.016 Zaragoza, 
4, 50.016 Zaragoza,
Rare side effects (may affect up to 1 in 1000 people) include lowering of normal body temperature; abnormal rhythms of the heart; sudden unexplained death; inflammation of the pancreas causing severe stomach pain, fever and sickness; liver disease appearing as yellowing of the skin and white parts of the eyes; muscle disease presenting as unexplained aches and pains; and prolonged and/or painful erection. 
Rijetke nuspojave (mogu se pojaviti u do 1 na 1000 osoba) uključuju sniženje normalne tjelesne temperature; poremećaj srčanog ritma; naglu neobjašnjivu smrt; upalu gušterače koja uzrokuje jaku bol u trbuhu, vrućicu i mučninu; bolest jetre koja se očituje žutilom kože i bjeloočnica; bolest mišića koja se manifestira neobjašnjivim bolovima; te produžena i/ili bolna erekcija.
Manic episode: The starting dose is 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy (see section 5.1). 
Epizoda manije: početna doza je 15 mg primjenjena kao jednokratna dnevna doza u monoterapiji ili 10
In cases where dose increments of 2.5 mg are considered necessary, Olanzapine Teva film-coated tablets should be used. 
U slučajevima kada je potrebno povećavati dozu u koracima od 2,5 mg treba primijeniti Olanzapin
Lemon flavour [flavouring preparation(s), maltodextrin, sucrose, gum arabic (E414), glyceryl triacetate (E1518) and alpha-Tocopherol (E307)] 
guma arabika (E414), gliceriltriacetat (E1518) i α-tokoferol (E307)].
Olanzapine Teva contains lactose, sucrose and aspartame This medicine contains lactose and sucrose. 
Olanzapin Teva sadrži laktozu, saharozu i aspartam
In healthy elderly (65 and over) versus non-elderly subjects, the mean elimination half-life was prolonged (51.8 versus 33.8 hr) and the clearance was reduced (17.5 versus 18.2 l/hr). 
U zdravih starijih ispitanika (65 godina i stariji) u odnosu na mlađe ispitanike srednja vrijednost poluvremena eliminacije bila je produžena (51,8 u odnosu na 33,8 sati), a klirens je bio smanjen (17,5
Patients gaining ≥7%, ≥15% and ≥25% of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4%, 31.7% and 12.3% respectively). 
Tijekom dugotrajne izloženosti lijeku (najmanje 48 tjedana), povećanje tjelesne težine ≥7%, ≥15% i ≥25% od početne bilo je vrlo često (64,4%, 31,7%, odnosno 12,3%).
Other symptoms may be: acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness, slowing of the breathing rate, aspiration, high blood pressure or low blood pressure, abnormal rhythms of the heart. 
kombinacija vrućice, ubrzanog disanja, znojenja, ukočenosti mišića i omamljenosti ili pospanosti, usporavanje disanja, aspiracija, visoki krvni tlak ili niski krvni tlak, poremećaj srčanog ritma.
If you notice any of these symptoms seek medical advice immediately; - a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness (the frequency of this side effect cannot be estimated from the available data). 
• kombinaciju vrućice, ubrzanog disanja, znojenja, ukočenosti mišića i omamljenosti ili pospanosti (učestalost ove nuspojave ne može se procijeniti iz dostupnih podataka).
Glutamyltransfera se10 
Visoka gama glutamiltransferaza10
Changes in fasting glucose from borderline at baseline (≥5.56-<7 mmol/l) to high (≥7 mmol/l) were very common. 
Promjene vrijednosti glukoze natašte od početnih graničnih vrijednosti (≥5,56-<7 mmol/l) do visokih vrijednosti (≥7 mmol/l) bile su vrlo česte.
Tablet coating: hypromellose, polydextrose, glycerol triacetate, macrogol 8000, titanium dioxide (E171). 
Ovojnica tablete: hipromeloza, polidekstroza, gliceroltriacetat, makrogol 8000, titanijev dioksid (E171).
Only take other medicines while you are on Olanzapine Teva if your doctor tells you that you can. You might feel drowsy if Olanzapine Teva is taken in combination with antidepressants or medicines taken for anxiety or to help you sleep (tranquillisers). 
Ako uzimate Olanzapin Teva u kombinaciji s antidepresivima ili lijekovima za tjeskobu ili lijekovima koji Vam pomažu zaspati (trankvilizeri), možete se osjećati pospano.
Hepatitis (including hepatocellular, cholestatic or mixed liver injury) 
hepatocelularno, kolestatsko ili mješovito oštećenje jetre)11
Excipient with known effect Each film-coated tablet contains 68.9 mg lactose. 
Svaka filmom obložena tableta sadrži 68,9 mg laktoze.
Each orodispersible tablet contains 142.5 mg lactose, 0.7875 mg sucrose and 6.75 mg aspartame (E951). 
Svaka raspadljiva tableta za usta sadrži 142,5 mg laktoze, 0,7875 mg saharoze i 6,75 mg aspartama (E951).
Changes in total fasting cholesterol levels from borderline at baseline (≥4.39-<5.17 mmol/l) to high (≥5.17 mmol/l) were very common. 
Vrlo česte su bile promjene ukupnih razina kolesterola natašte od graničnih početnih vrijednosti (≥4,39-<5,17 mmol/l) do visokih (≥5,17 mmol/l).
Your doctor should do blood tests to check blood sugar and certain fat levels before you start taking Olanzapine Teva and regularly during treatment. 
Prije početka uzimanja Olanzapina Teva te redovito tijekom liječenja, liječnik bi Vam trebao obaviti krvne pretrage kako bi provjerio razinu šećera i određenih masnoća u krvi.
3 Observed for fasting normal levels at baseline (<5.17 mmol/l) which increased to high (≥6.2 mmol/l). 
3 Uočeno za početne normalne razine natašte (<5,17 mmol/l) koje su porasle na visoke razine (≥6,2 mmol/l).
Hepatic function 
Hepatitis
Children and adolescents Olanzapine Teva is not for patients who are under 18 years. 
Olanzapin Teva nije za primjenu u bolesnika mlađih od 18 godina.
Olanzapine Teva contains lactose 
Olanzapin Teva sadrži laktozu
Poligono Industrial Malpica, c/C, no. 4 50.016 Zaragoza 
4 50.016 Zaragoza
Hepatitis (including hepatocellular, cholestatic or aminotransferases (ALT, AST), especially in early treatment (see section 4.4) 
(uključujući hepatocelularno, kolestatsko ili jetre (ALT, AST), osobito na početku liječenja
Each orodispersible tablet contains 190.0 mg lactose, 1.05 mg sucrose and 9.0 mg aspartame (E951). 
Svaka raspadljiva tableta za usta sadrži 190,0 mg laktoze, 1,05 mg saharoze i 9,0 mg aspartama (E951).
Excipient with known effect Each film-coated tablet contains 206.7 mg lactose. 
Svaka filmom obložena tableta sadrži 206,7 mg laktoze.
If you suddenly stop taking Olanzapine Teva, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur. 
Ako naglo prestanete s uzimanjem Olanzapin Teva mogu se pojaviti simptomi poput znojenja,
5 Observed for fasting normal levels at baseline (<1.69 mmol/l) which increased to high 
Uočeno za početne normalne razine natašte (<1,69 mmol/l) koje su porasle na visoke razine
(≥ 1.016 mmol/l-<1.467 mmol/l) to high (≥1.467 mmol/l). 
14 Uočeno za normalne početne razine triglicerida natašte (<1,016 mmol/l) koje su porasle na visoke razine (≥1,467 mmol/l) i promjene vrijednosti triglicerida natašte od početnih graničnih vrijednosti (≥1,016 mmol/l-<1,467 mmol/l) do visokih vrijednosti (≥1,467 mmol/l).
Other medically significant sequelae of overdose include delirium, convulsion, coma, possible neuroleptic malignant syndrome, respiratory depression, aspiration, hypertension or hypotension, 
Druge medicinski značajne posljedice predoziranja obuhvaćaju delirij, konvulzije, komu, mogući neuroleptički maligni sindrom, respiratornu depresiju, aspiraciju, hipertenziju ili hipotenziju, srčane aritmije (<2% slučajeva predoziranja) i kardiopulmonalni arest.
Tablet core: lactose monohydrate, hydroxypropylcellulose, crospovidone (type A), silica colloidal anhydrous, microcrystalline cellulose, magnesium stearate. 
Jezgra tablete: laktoza hidrat, hidroksipropilceluloza, krospovidon (vrste A), silicijev dioksid,
Common side effects (may affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating fats and early in treatment, temporary increases in liver enzymes; increases in the level of sugars in the blood and urine; increases in levels of uric acid and creatine phosphokinase in the blood; feeling more hungry; dizziness; restlessness; tremor; unusual movements (dyskinesias); constipation; dry mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling of the hands, ankles or feet; fever; joint pain; and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males 
Česte nuspojave (mogu se pojaviti u manje od 1 na 10 osoba) uključuju promjene razina nekih krvnih stanica i cirkulirajućih masti u krvi te, u ranim fazama liječenja, privremena povećanja razine jetrenih enzima; povišene razine šećera u krvi i mokraći; povećanje razine mokraćne kiseline i kreatin fosfokinaze u krvi; pojačan apetit; omaglicu; nemir; nevoljno drhtanje;neuobičajene pokrete (diskinezije); zatvor; suha usta; osip; slabost; pojačani umor; zadržavanje vode u tijelu koje dovodi do otečenosti ruku, zglobova ili stopala; vrućicu, bol u zglobovima te seksualne poremećaje kao što su smanjeni libido u muškaraca i žena ili erektilna disfunkcija u muškaraca.
Excipient with known effect Each film-coated tablet contains 103.3 mg lactose. 
Svaka filmom obložena tableta sadrži 103,3 mg laktoze.
- The other ingredients are mannitol, aspartame (E951), magnesium stearate, crospovidone type B, lactose monohydrate, hydroxypropylcellulose and lemon flavour [flavouring preparation(s), maltodextrin, sucrose, gum arabic (E414), glyceryl triacetate (E1518) and alphatocopherol (E307)]. 
6.1 Popis pomoćnih tvari manitol aspartam (E951) magnezijev stearat krospovidon vrste B laktoza hidrat hidroksipropilceluloza okus limuna [smjesa za aromatiziranje, maltodekstrin, saharoza, guma arabika (E414), gliceriltriacetat (E1518) i α-Tokoferol (E307)]
Excipient with known effect Each film-coated tablet contains 275.5 mg lactose. 
Svaka filmom obložena tableta sadrži 275,5 mg laktoze.
Olanzapine Teva 2.5 mg film-coated tablets Olanzapine Teva 5 mg film-coated tablets Olanzapine Teva 7.5 mg film-coated tablets Olanzapine Teva 10 mg film-coated tablets Olanzapine Teva 15 mg film-coated tablets Olanzapine Teva 20 mg film-coated tablets 
Olanzapin Teva 2,5 mg filmom obložene tablete Olanzapin Teva 5 mg filmom obložene tablete Olanzapin Teva 7,5 mg filmom obložene tablete Olanzapin Teva 10 mg filmom obložene tablete Olanzapin Teva 15 mg filmom obložene tablete Olanzapin Teva 20 mg filmom obložene tablete
4 Observed for fasting normal levels at baseline (<5.56 mmol/l) which increased to high (≥7 mmol/l). 
Uočeno za početne normalne razine natašte (<5,56 mmol/l) koje su porasle na visoke razine (≥7 mmol/l).
Leukopenia10 
Leukopenija10 Neutropenija10
Olanzapine Teva 5 mg orodispersible tablets Olanzapine Teva 10 mg orodispersible tablets Olanzapine Teva 15 mg orodispersible tablets Olanzapine Teva 20 mg orodispersible tablets 
Olanzapin Teva 5 mg raspadljive tablete za usta Olanzapin Teva 10 mg raspadljive tablete za usta Olanzapin Teva 15 mg raspadljive tablete za usta Olanzapin Teva 20 mg raspadljive tablete za usta
Olanzapine Teva 5 mg, 10 mg and 15 mg orodispersible tablets are available in cartons containing 28, 30, 35, 50, 56, 70 or 98 tablets. 
Olanzapin Teva 5 mg, 10 mg i 15 mg raspadljive tablete za usta su dostupne u kutijama s 28, 30, 35, 50, 56, 70 ili 98 tableta.
13 Following short term treatment (median duration 22 days), weight gain ≥7% of baseline body weight (kg) was very common (40.6%), ≥15% of baseline body weight was common (7.1%) and 
13 Nakon kratkotrajnog liječenja (medijan trajanja 22 dana), povećanje tjelesne težine ≥7% od početne tjelesne težine (kg) bilo je vrlo često (40,6%), porast ≥15% od početne tjelesne težine bio je čest
Olanzapine Teva belongs to a group of medicines called antipsychotics and is used to treat the following conditions: - Schizophrenia, a disease with symptoms such as hearing, seeing or sensing things which are not there, mistaken beliefs, unusual suspiciousness, and becoming withdrawn. 
• Shizofrenije, bolesti sa simptomima kao što su slušna, vidna ili osjetilna priviđenja stvari koje nisu prisutne, iluzije, neuobičajena sumnjičavost i povučenost.
Lactose monohydrate Hydroxypropylcellulose Crospovidone type A Silica colloidal anhydrous Microcrystalline cellulose Magnesium stearate 
Jezgra tablete laktoza hidrat hidroksipropilceluloza krospovidon vrste
Excipient with known effect Each film-coated tablet contains 137.8 mg lactose. 
Svaka filmom obložena tableta sadrži 137,8 mg laktoze.
However, caution should be exercised when olanzapine is prescribed with medicines known to increase QTc interval, especially in the elderly, in patients with congenital long QT syndrome, congestive heart failure, heart hypertrophy, hypokalaemia or hypomagnesaemia. 
osobito u starijih osoba, u bolesnika s prirođenim sindromom dugog QT-intervala, kongestivnim zatajenjem srca, hipertrofijom srca, hipokalijemijom ili hipomagnezemijom.
Each orodispersible tablet contains 47.5 mg lactose, 0.2625 mg sucrose and 2.25 mg aspartame (E951). 
Svaka raspadljiva tableta za usta sadrži 47,5 mg laktoze, 0,2625 mg saharoze i 2,25 mg aspartama (E951).
Pyrexia10 
Artralgija9
Excipient with known effect Each film-coated tablet contains 71.3 mg lactose. 
Svaka filmom obložena tableta sadrži 71,3 mg laktoze.
3 Observed for fasting normal levels at baseline (<5.17 mmol/l) which increased to high 
3 Uočeno za početne normalne razine natašte (<5,17 mmol/l) koje su porasle na visoke razine
15 Changes in total fasting cholesterol levels from normal at baseline (<4.39 mmol/l) to high 
15 Često su uočene promjene ukupnog kolesterola natašte od normalnih početnih vrijednosti (<4,39 mmol/l) do visokih vrijednosti (≥5,17 mmol/l).
Each Olanzapine Teva 7.5 mg film-coated tablet contains 7.5 mg of the active substance. 
Jedna Olanzapin Teva 7,5 mg filmom obložena tableta sadrži 7,5 mg djelatne tvari.
Olanzapine Teva 7.5 mg film-coated tablets 
Olanzapin Teva 7,5 mg filmom obložene tablete
Tell your doctor immediately if you have: - unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face or tongue; - blood clots in the veins (an uncommon side effect that may affect up to 1 in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing. 
• krvne ugruške u venama (manje česta nuspojava koja se može pojaviti u manje od 1 na 100 osoba), posebno u nogama (simptomi uključuju oticanje, bol i crvenilo nogu), koji može putovati krvnim žilama do pluća uzrokujući bol u prsima i otežano disanje.
- High blood sugar and high levels of fat (triglycerides and cholesterol) have been seen in patients taking Olanzapine Teva. 
- U bolesnika koji uzimaju Olanzapin Teva uočena je visoka razina šećera i masnoća u krvi (trigliceridi i kolesterol).
Amenorrhea Breast enlargement Galactorrhea in females 
Galaktoreja u žena Ginekomastija/pove ćanje dojki u muškaraca
Olanzapine Teva 7.5 mg film-coated tablets Each film-coated tablet contains 7.5 mg olanzapine. 
Olanzapin Teva 7,5 mg filmom obložene tablete Svaka filmom obložena tableta sadrži 7,5 mg olanzapina.
The mean increase in olanzapine AUC was 52% and 108% respectively. 
Srednja vrijednost porasta AUC olanzapina iznosila je 52% u žena nepušača, odnosno 108% u muškaraca pušača.
Investigations Elevated plasma prolactin levels8 
Povišene razine prolaktina u plazmi8
Olanzapine Teva 20 mg film-coated tablets Each film-coated tablet contains 20 mg olanzapine. 
Olanzapin Teva 20 mg filmom obložene tablete Svaka filmom obložena tableta sadrži 20 mg olanzapina.
Each orodispersible tablet contains 95.0 mg lactose, 0.525 mg sucrose and 4.5 mg aspartame (E951). 
Svaka raspadljiva tableta za usta sadrži 95,0 mg laktoze, 0,525 mg saharoze i 4,5 mg aspartama (E951).
A mass balance study showed that approximately 57% of radiolabelled olanzapine appeared in urine, principally as metabolites. 
olanzapina označenog radioizotopom pojavljuje u mokraći, uglavnom u obliku metabolita.
Uncommon side effects (may affect up to 1 in 100 people) include hypersensitivity (e.g. swelling in the mouth and throat, itching, rash); diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma; seizures, usually associated with a history of seizures (epilepsy); muscle stiffness or spasms (including eye movements); restless legs syndrome; problems with speech; stuttering; slow heart rate; sensitivity to sunlight; bleeding from the nose; abdominal distension; memory loss or forgetfulness; urinary incontinence; lack of ability to urinate; hair loss; absence or decrease in menstrual periods; and changes in breasts in males and females such as an abnormal production of breast milk or abnormal growth. 
Manje česte nuspojave (mogu se pojaviti u manje od 1 na 100 osoba) uključuju preosjetljivost (npr. oticanje u ustima i grlu, svrbež; osip); šećernu bolest ili pogoršanje šećerne bolesti, ponekad povezano s ketoacidozom (ketonima u krvi i mokraći) ili komom; napadaje, obično povezane s napadajima u povijesti bolesti (epilepsija); mišićnu ukočenost ili grč (uključujući pokrete očiju); sindrom nemirnih nogu; poteškoće s govorom; mucanje; usporen rad srca; osjetljivost na sunčevu svjetlost; krvarenje iz nosa; nadimanje trbuha; gubitak pamćenja ili zaboravljivost; nemogućnost mokrenja; ispadanje kose;
Drug withdrawal syndrome neonatal (see section 4.6) 
Sindrom ustezanja u novorođenč adi (vidjeti dio 4.6)
Each Olanzapine Teva 20 mg film-coated tablet contains 20 mg of the active substance. 
Jedna Olanzapin Teva 20 mg filmom obložena tableta sadrži 20 mg djelatne tvari.
Hepatobiliary disorders Transient, asymptomatic elevations of hepatic 
Prolazni asimptomatski porast razina aminotransferaza
Each Olanzapine Teva 2.5 mg film-coated tablet contains 2.5 mg of the active substance. 
Jedna Olanzapin Teva 2,5 mg filmom obložena tableta sadrži 2,5 mg djelatne tvari.
Blood and the lymphatic system disorders Eosinophilia 
Poremećaji krvi i limfnog sustava
In studies up to 3 months duration in mice and up to 1 year in rats and dogs, the predominant effects were CNS depression, anticholinergic effects, and peripheral haematological disorders. 
U ispitivanjima u trajanju do 3 mjeseca na miševima te do godine dana na štakorima i psima,